These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 33304270)

  • 1. Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective.
    Yu W; Cheng JD
    Front Pharmacol; 2020; 11():582680. PubMed ID: 33304270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications.
    Si K; Wei C; Xu L; Zhou Y; Lv W; Dong B; Wang Z; Huang Y; Wang Y; Chen Y
    Front Endocrinol (Lausanne); 2021; 12():770815. PubMed ID: 34867815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Safety of Urate Lowering Therapies.
    Kang EH; Kim SC
    Curr Rheumatol Rep; 2019 Jul; 21(9):48. PubMed ID: 31342190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
    Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
    Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition.
    Harzand A; Tamariz L; Hare JM
    Congest Heart Fail; 2012; 18(3):179-82. PubMed ID: 22587748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
    Pan JA; Lin H; Wang CQ; Zhang JF; Gu J
    Heart Vessels; 2020 Oct; 35(10):1446-1453. PubMed ID: 32430700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
    Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
    Tanaka A; Taguchi I; Teragawa H; Ishizaka N; Kanzaki Y; Tomiyama H; Sata M; Sezai A; Eguchi K; Kato T; Toyoda S; Ishibashi R; Kario K; Ishizu T; Ueda S; Maemura K; Higashi Y; Yamada H; Ohishi M; Yokote K; Murohara T; Oyama JI; Node K;
    PLoS Med; 2020 Apr; 17(4):e1003095. PubMed ID: 32320401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK; Singh JA
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linking uric acid metabolism to diabetic complications.
    Kushiyama A; Tanaka K; Hara S; Kawazu S
    World J Diabetes; 2014 Dec; 5(6):787-95. PubMed ID: 25512781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
    Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
    Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy.
    Lee TH; Chen JJ; Wu CY; Yang CW; Yang HY
    Diagnostics (Basel); 2021 Sep; 11(9):. PubMed ID: 34574015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
    Borghi C; Agabiti-Rosei E; Johnson RJ; Kielstein JT; Lurbe E; Mancia G; Redon J; Stack AG; Tsioufis KP
    Eur J Intern Med; 2020 Oct; 80():1-11. PubMed ID: 32739239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pharmacological reversal of hyperuricemia on features of the metabolic syndrome in patients with gouty arthritis.
    Marin M; Maalouf NM
    J Investig Med; 2018 Oct; 66(7):1031-1036. PubMed ID: 29622755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
    Chen C; Lü JM; Yao Q
    Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
    Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
    J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
    Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
    Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
    Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.